# Tr1x

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tr1x

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.tr1x.bio
- Total disclosed funding: $63M
- Latest round: Series A (Dec 31, 2023)
- Investors on record: 3

## About

Based in California, US, and founded in 2018 by Professor Maria Grazia Roncarolo, Tr1x Inc. operates as a biotechnology company focused on engineering cures for autoimmune and inflammatory diseases. In January 2024, Tr1x, Inc. raised USD 75 million in series A funding led by The Column Group, with participation from Neva. Alexandria Venture Investments also participated in the round.

Tr1x Inc. is engaged in the development of cellular therapies with the potential to cure disease by inducing immune tolerance and restoring homeostasis through the engineering of T cells. Tr1x Inc. has a state-of-the-art technology platform that allows for the scalable generation of engineered living drugs to help patients suffering from debilitating diseases with high unmet medical needs.

## Funding rounds

- Series A, Dec 31, 2023, $49M — Alexandria Venture Investments, The Column Group, Neva
- Series A, Jun 29, 2022, $14M — Neva

## Investors

- Neva (https://capitalatlas.ai/funds/neva) — Series A
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- The Column Group (https://capitalatlas.ai/funds/the-column-group) — Series A